Currently, the GPHC's portfolio includes 11 own Market Authorizations of parenteral antibiotics.
Antibiotics are available in a wide range of dosages, as well as in forms of monopreparations and fixed combinations for a more convenient and correct prescription of antibacterial therapy.
Antibiotics are available in a wide range of dosages, as well as in forms of monopreparations and fixed combinations for a more convenient and correct prescription of antibacterial therapy.
2 INN
At present, there are more than 10 antibacterial drugs in development process aimed to meet the basic requirements of the medical specialists. Active preparations are underway for the production of medicines for the treatment of patients with cardiological, endocrinological, and nephrological profiles. Medicines for a treatment of oncological and hematological patients are in the final stages of development.
In the second quarter of 2024, it is planned to launch a registration Clinical Trial (Phase III) of an original antibacterial medicine of foreign production, which GPHC will present on a basis of exclusivity.
